The global personalized cell therapy market, by Cell Type (Lymphocytes, Mesenchymal Stem Cell, Hematopoietic Stem Cell, and Others), by Therapeutic Area (Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, and Cancer), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 8,046.3 million in 2018, and is expected to exhibit a CAGR of 23.5% over the forecast period (2019 - 2027). Manufacturer are focusing on expansion of their manufacturing facilities, in order to produce cell therapy candidates in large volume. With this, manufactures can penetrate into large untapped markets in emerging economies, which can increase the number of personalized cell therapy manufacturing procedures worldwide. For instance, in April 2019, Kite, a subsidiary of Gilead Company, announced to build a new production facility in Frederick County, Maryland, U.S. to produce innovative personalized cell therapies for treatment of cancer.
Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on ‘Personalized Cell Therapy Market, by, by Cell Type (Lymphocytes, Mesenchymal Stem Cell, Hematopoietic Stem Cell, and Others), by Therapeutic Area (Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, and Cancer), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), Global Forecast to 2027’
To know the latest trends and insights related to global personalized cell therapy market, click the link below:
Increasing regulatory approval for investigational personalized cell therapy candidates is expected to show significant personalized cell therapy market growth over the forecast period. For instance, in July 2019, Personalized Stem Cells Inc. received the U.S. FDA approval for its investigational new drug application that involves usage of adipose-derived stem cells for the treatment of osteoarthritis. For this new therapy candidates, Personalized Stem Cells Inc. initiated the first clinical trial in August 2019, in which the company used stem cells to treat knee osteoarthritis. Rising adoption of inorganic strategies such as partnerships and joint ventures by major players is anticipated to drive the personalized cell therapy market growth. For instance, in December 2016, Bayer AG and Versant Ventures launched its joint venture BlueRock Therapeutics, a next-generation regenerative medicine company, to develop induced pluripotent stem cell (iPSC) therapies to cure a range of diseases. Moreover, Bayer and Versant invested US$ 225 million to enabled and strengthen BlueRock Therapeutics’ manufacturing platform and product pipeline.
Startup biotech companies are also focusing on the development of the personalized cell therapies, thereby driving the personalized cell therapy market growth. For instance, in October 2019, ElevateBio, U.S.-based cell and gene therapy developer, initiated a new startup, HighPassBio, to develop novel T cell immunotherapies. In 2019, the company initiated Phase 1 clinical trial on an engineered T cell receptor (TCR) T cell therapy for HA-1 expressing tumors targeting relapse of leukemia following hematopoietic stem cell transplant (HSCT).
Key Takeaways of the Global Personalized Cell Therapy Market: